Skip to main content
Erschienen in: Medical Oncology 4/2012

01.12.2012 | Original Paper

The -938A/A genotype of BCL2 gene is associated with esophageal cancer

verfasst von: Zhigang Liu, Ruifang Sun, Weidong Lü, Chengxue Dang, Yangrong Song, Cheng Wang, Xi Zhang, Le Han, Hao Cheng, Wei Gao, Jia Liu, Guangyan Lei

Erschienen in: Medical Oncology | Ausgabe 4/2012

Einloggen, um Zugang zu erhalten

Abstract

Perturbations in the apoptotic genes have been implicated in human malignancies. The purpose of the present study was to investigate the polymorphisms of -938C/A, Thr43Ala in anti-apoptotic B-cell lymphoma 2 gene (BCL2) and -248G/A in pro-apoptotic B-cell lymphoma 2-associated X protein gene (BAX) and to explore their role in influencing the susceptibility for development of esophageal cancer. A total of 205 esophageal cancer patients and 224 controls were enrolled in the present study. The genotype and allele distributions of -938C/A, ala43thr in BCL2 and -248G/A in BAX were analyzed in patients and controls, as well as the association of -938C/A genotype with clinical characteristics in patients. We found that homozygous -938A/A genotype of BCL2 gene was significantly associated with risk of developing esophageal cancer (χ2 = 9.269, P = 0.002, OR = 2.585, 95%CI = 1.380–4.842). Association with clinical characteristics showed that the patients with BCL2 -938A/A genotype were more likely to develop into poor differentiation compared with the AC and CC carriers (χ2 = 5.796, P = 0.016, OR = 4.039, 95%CI = 1.200–13.596), and we found smokers were more present in the -938A/A genotype subgroup (χ2 = 5.095, P = 0.024, OR = 2.679, 95%CI = 0.893–8.025). The present study revealed that the -938A/A genotype of BCL2 gene is associated with susceptibility of esophageal cancer. There appeared to be an impact of BCL2 -938A/A genotype on tumor differentiation and smoking. Further studies are needed in a larger population.
Literatur
1.
Zurück zum Zitat He J, Gu D, Wu X, Reynolds K, Duan X, Yao C, Wang J, Chen CS, Chen J, Wildman RP, et al. Major causes of death among men and women in China. N Engl J Med. 2005;353(11):1124–34.PubMedCrossRef He J, Gu D, Wu X, Reynolds K, Duan X, Yao C, Wang J, Chen CS, Chen J, Wildman RP, et al. Major causes of death among men and women in China. N Engl J Med. 2005;353(11):1124–34.PubMedCrossRef
2.
Zurück zum Zitat Holmes RS, Vaughan TL. Epidemiology and pathogenesis of esophageal cancer. Semin Radiat Oncol. 2007;17(1):2–9.PubMedCrossRef Holmes RS, Vaughan TL. Epidemiology and pathogenesis of esophageal cancer. Semin Radiat Oncol. 2007;17(1):2–9.PubMedCrossRef
3.
Zurück zum Zitat Hao B, Wang H, Zhou K, Li Y, Chen X, Zhou G, Zhu Y, Miao X, Tan W, Wei Q. Identification of genetic variants in base excision repair pathway and their associations with risk of esophageal squamous cell carcinoma. Cancer Res. 2004;64(12):4378–84.PubMedCrossRef Hao B, Wang H, Zhou K, Li Y, Chen X, Zhou G, Zhu Y, Miao X, Tan W, Wei Q. Identification of genetic variants in base excision repair pathway and their associations with risk of esophageal squamous cell carcinoma. Cancer Res. 2004;64(12):4378–84.PubMedCrossRef
4.
Zurück zum Zitat Tang DG, Porter AT. Target to apoptosis: a hopeful weapon for prostate cancer. Prostate. 1997;32(4):284–93.PubMedCrossRef Tang DG, Porter AT. Target to apoptosis: a hopeful weapon for prostate cancer. Prostate. 1997;32(4):284–93.PubMedCrossRef
5.
Zurück zum Zitat Faderl S, Keating MJ, Do KA, Liang SY, Kantarjian HM, O’Brien S, Garcia-Manero G, Manshouri T, Albitar M. Expression profile of 11 proteins and their prognostic significance in patients with chronic lymphocytic leukemia (CLL). Leukemia. 2002;16(6):1045–52.PubMedCrossRef Faderl S, Keating MJ, Do KA, Liang SY, Kantarjian HM, O’Brien S, Garcia-Manero G, Manshouri T, Albitar M. Expression profile of 11 proteins and their prognostic significance in patients with chronic lymphocytic leukemia (CLL). Leukemia. 2002;16(6):1045–52.PubMedCrossRef
6.
Zurück zum Zitat Keshgegian AA, Johnston E, Cnaan A. Bcl-2 oncoprotein positivity and high MIB-1 (Ki-67) proliferative rate are independent predictive markers for recurrence in prostate carcinoma. Am J Clin Pathol. 1998;110(4):443–9.PubMed Keshgegian AA, Johnston E, Cnaan A. Bcl-2 oncoprotein positivity and high MIB-1 (Ki-67) proliferative rate are independent predictive markers for recurrence in prostate carcinoma. Am J Clin Pathol. 1998;110(4):443–9.PubMed
7.
Zurück zum Zitat Ofner D, Riehemann K, Maier H, Riedmann B, Nehoda H, Totsch M, Bocker W, Jasani B, Schmid KW. Immunohistochemically detectable bcl-2 expression in colorectal carcinoma: correlation with tumour stage and patient survival. Br J Cancer. 1995;72(4):981–5.PubMedCrossRef Ofner D, Riehemann K, Maier H, Riedmann B, Nehoda H, Totsch M, Bocker W, Jasani B, Schmid KW. Immunohistochemically detectable bcl-2 expression in colorectal carcinoma: correlation with tumour stage and patient survival. Br J Cancer. 1995;72(4):981–5.PubMedCrossRef
8.
Zurück zum Zitat Zhang GJ, Kimijima I, Tsuchiya A, Abe R. The role of bcl-2 expression in breast carcinomas (Review). Oncol Rep. 1998;5(5):1211–6.PubMed Zhang GJ, Kimijima I, Tsuchiya A, Abe R. The role of bcl-2 expression in breast carcinomas (Review). Oncol Rep. 1998;5(5):1211–6.PubMed
9.
Zurück zum Zitat Fontanini G, Vignati S, Bigini D, Mussi A, Lucchi M, Angeletti CA, Basolo F, Bevilacqua G. Bcl-2 protein: a prognostic factor inversely correlated to p53 in non-small-cell lung cancer. Br J Cancer. 1995;71(5):1003–7.PubMedCrossRef Fontanini G, Vignati S, Bigini D, Mussi A, Lucchi M, Angeletti CA, Basolo F, Bevilacqua G. Bcl-2 protein: a prognostic factor inversely correlated to p53 in non-small-cell lung cancer. Br J Cancer. 1995;71(5):1003–7.PubMedCrossRef
10.
Zurück zum Zitat Hirata H, Hinoda Y, Nakajima K, Kikuno N, Suehiro Y, Tabatabai ZL, Ishii N, Dahiya R. The bcl2–938CC genotype has poor prognosis and lower survival in renal cancer. J Urol. 2009;182(2):721–7.PubMedCrossRef Hirata H, Hinoda Y, Nakajima K, Kikuno N, Suehiro Y, Tabatabai ZL, Ishii N, Dahiya R. The bcl2–938CC genotype has poor prognosis and lower survival in renal cancer. J Urol. 2009;182(2):721–7.PubMedCrossRef
11.
Zurück zum Zitat Lehnerdt GF, Franz P, Bankfalvi A, Grehl S, Kelava A, Nuckel H, Lang S, Schmid KW, Siffert W, Bachmann HS. The regulatory BCL2 promoter polymorphism (-938C>A) is associated with relapse and survival of patients with oropharyngeal squamous cell carcinoma. Ann Oncol. 2009;20(6):1094–9.PubMedCrossRef Lehnerdt GF, Franz P, Bankfalvi A, Grehl S, Kelava A, Nuckel H, Lang S, Schmid KW, Siffert W, Bachmann HS. The regulatory BCL2 promoter polymorphism (-938C>A) is associated with relapse and survival of patients with oropharyngeal squamous cell carcinoma. Ann Oncol. 2009;20(6):1094–9.PubMedCrossRef
12.
Zurück zum Zitat Aguilar-Santelises M, Rottenberg ME, Lewin N, Mellstedt H, Jondal M. Bcl-2, Bax and p53 expression in B-CLL in relation to in vitro survival and clinical progression. Int J Cancer. 1996;69(2):114–9.PubMedCrossRef Aguilar-Santelises M, Rottenberg ME, Lewin N, Mellstedt H, Jondal M. Bcl-2, Bax and p53 expression in B-CLL in relation to in vitro survival and clinical progression. Int J Cancer. 1996;69(2):114–9.PubMedCrossRef
13.
Zurück zum Zitat Pepper C, Hoy T, Bentley DP. Bcl-2/Bax ratios in chronic lymphocytic leukaemia and their correlation with in vitro apoptosis and clinical resistance. Br J Cancer. 1997;76(7):935–8.PubMedCrossRef Pepper C, Hoy T, Bentley DP. Bcl-2/Bax ratios in chronic lymphocytic leukaemia and their correlation with in vitro apoptosis and clinical resistance. Br J Cancer. 1997;76(7):935–8.PubMedCrossRef
14.
Zurück zum Zitat Kidd LR, Coulibaly A, Templeton TM, Chen W, Long LO, Mason T, Bonilla C, Akereyeni F, Freeman V, Isaacs W, et al. Germline BCL-2 sequence variants and inherited predisposition to prostate cancer. Prostate Cancer Prostatic Dis. 2006;9(3):284–92.PubMedCrossRef Kidd LR, Coulibaly A, Templeton TM, Chen W, Long LO, Mason T, Bonilla C, Akereyeni F, Freeman V, Isaacs W, et al. Germline BCL-2 sequence variants and inherited predisposition to prostate cancer. Prostate Cancer Prostatic Dis. 2006;9(3):284–92.PubMedCrossRef
15.
Zurück zum Zitat Chen K, Hu Z, Wang LE, Sturgis EM, El-Naggar AK, Zhang W, Wei Q. Single-nucleotide polymorphisms at the TP53-binding or responsive promoter regions of BAX and BCL2 genes and risk of squamous cell carcinoma of the head and neck. Carcinogenesis. 2007;28(9):2008–12.PubMedCrossRef Chen K, Hu Z, Wang LE, Sturgis EM, El-Naggar AK, Zhang W, Wei Q. Single-nucleotide polymorphisms at the TP53-binding or responsive promoter regions of BAX and BCL2 genes and risk of squamous cell carcinoma of the head and neck. Carcinogenesis. 2007;28(9):2008–12.PubMedCrossRef
16.
Zurück zum Zitat Komaki S, Kohno M, Matsuura N, Shimadzu M, Adachi N, Hoshide R, Nishiyama S, Matsuda I. The polymorphic 43Thr bcl-2 protein confers relative resistance to autoimmunity: an analytical evaluation. Hum Genet. 1998;103(4):435–40.PubMedCrossRef Komaki S, Kohno M, Matsuura N, Shimadzu M, Adachi N, Hoshide R, Nishiyama S, Matsuda I. The polymorphic 43Thr bcl-2 protein confers relative resistance to autoimmunity: an analytical evaluation. Hum Genet. 1998;103(4):435–40.PubMedCrossRef
17.
Zurück zum Zitat Jain M, Kumar S, Lal P, Tiwari A, Ghoshal UC, Mittal B. Role of BCL2 (ala43thr), CCND1 (G870A) and FAS (A-670G) polymorphisms in modulating the risk of developing esophageal cancer. Cancer Detect Prev. 2007;31(3):225–32.PubMedCrossRef Jain M, Kumar S, Lal P, Tiwari A, Ghoshal UC, Mittal B. Role of BCL2 (ala43thr), CCND1 (G870A) and FAS (A-670G) polymorphisms in modulating the risk of developing esophageal cancer. Cancer Detect Prev. 2007;31(3):225–32.PubMedCrossRef
18.
Zurück zum Zitat Fegan C, Starczynski J, Pratt G, Pepper C. The role of the bax gene polymorphism G(-248)A in chronic lymphocytic leukemia. Leukemia. 2006;20(8):1460–1.PubMedCrossRef Fegan C, Starczynski J, Pratt G, Pepper C. The role of the bax gene polymorphism G(-248)A in chronic lymphocytic leukemia. Leukemia. 2006;20(8):1460–1.PubMedCrossRef
19.
Zurück zum Zitat Nuckel H, Frey UH, Sellmann L, Bau M, Durig J, Duhrsen U, Siffert W. Bax gene G(-248)A promoter polymorphism and chronic lymphocytic leukemia: lack of association with incidence, disease stage and progression-free survival. Leukemia. 2006;20(4):724.PubMedCrossRef Nuckel H, Frey UH, Sellmann L, Bau M, Durig J, Duhrsen U, Siffert W. Bax gene G(-248)A promoter polymorphism and chronic lymphocytic leukemia: lack of association with incidence, disease stage and progression-free survival. Leukemia. 2006;20(4):724.PubMedCrossRef
20.
Zurück zum Zitat Skogsberg S, Tobin G, Krober A, Kienle D, Thunberg U, Aleskog A, Karlsson K, Laurell A, Merup M, Vilpo J, et al. The G(-248)A polymorphism in the promoter region of the Bax gene does not correlate with prognostic markers or overall survival in chronic lymphocytic leukemia. Leukemia. 2006;20(1):77–81.PubMedCrossRef Skogsberg S, Tobin G, Krober A, Kienle D, Thunberg U, Aleskog A, Karlsson K, Laurell A, Merup M, Vilpo J, et al. The G(-248)A polymorphism in the promoter region of the Bax gene does not correlate with prognostic markers or overall survival in chronic lymphocytic leukemia. Leukemia. 2006;20(1):77–81.PubMedCrossRef
21.
Zurück zum Zitat Watanabe H, Jass JR, Sobin LH, Ōta K. International histological classification of tumors. 2nd ed. Berlin, New York: Springer-Verlag; 1990. Watanabe H, Jass JR, Sobin LH, Ōta K. International histological classification of tumors. 2nd ed. Berlin, New York: Springer-Verlag; 1990.
22.
Zurück zum Zitat Zhang N, Li XY, Tao K, Jiang LY, Ma TT, Yan S, Yuan CZ, Moran MS, Liang FM, Haffty BG, et al. BCL-2 (-938C > A) polymorphism is associated with breast cancer susceptibility. BMC Med Genet. 2011. doi:10.1186/1471-2350-12-48. Zhang N, Li XY, Tao K, Jiang LY, Ma TT, Yan S, Yuan CZ, Moran MS, Liang FM, Haffty BG, et al. BCL-2 (-938C > A) polymorphism is associated with breast cancer susceptibility. BMC Med Genet. 2011. doi:10.​1186/​1471-2350-12-48.
23.
Zurück zum Zitat Ocana MG, Valle-Garay E, Montes AH, Meana A, Carton JA, Fierer J, Celada A, Asensi V. Bax gene G(-248)A promoter polymorphism is associated with increased lifespan of the neutrophils of patients with osteomyelitis. Genet Med. 2007;9(4):249–55.PubMedCrossRef Ocana MG, Valle-Garay E, Montes AH, Meana A, Carton JA, Fierer J, Celada A, Asensi V. Bax gene G(-248)A promoter polymorphism is associated with increased lifespan of the neutrophils of patients with osteomyelitis. Genet Med. 2007;9(4):249–55.PubMedCrossRef
24.
Zurück zum Zitat Hockenbery D, Nunez G, Milliman C, Schreiber RD, Korsmeyer SJ. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature. 1990;348(6299):334–6.PubMedCrossRef Hockenbery D, Nunez G, Milliman C, Schreiber RD, Korsmeyer SJ. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature. 1990;348(6299):334–6.PubMedCrossRef
25.
Zurück zum Zitat Metzger R, Schneider PM, Warnecke-Eberz U, Brabender J, Holscher AH. Molecular biology of esophageal cancer. Onkologie. 2004;27(2):200–6.PubMedCrossRef Metzger R, Schneider PM, Warnecke-Eberz U, Brabender J, Holscher AH. Molecular biology of esophageal cancer. Onkologie. 2004;27(2):200–6.PubMedCrossRef
26.
Zurück zum Zitat Ohbu M, Saegusa M, Kobayashi N, Tsukamoto H, Mieno H, Kakita A, Okayasu I. Expression of bcl-2 protein in esophageal squamous cell carcinomas and its association with lymph node metastasis. Cancer. 1997;79(7):1287–93.PubMedCrossRef Ohbu M, Saegusa M, Kobayashi N, Tsukamoto H, Mieno H, Kakita A, Okayasu I. Expression of bcl-2 protein in esophageal squamous cell carcinomas and its association with lymph node metastasis. Cancer. 1997;79(7):1287–93.PubMedCrossRef
27.
Zurück zum Zitat Park BL, Kim LH, Cheong HS, Cho HY, Kim EM, Shin HD, Kim YS, Lee C. Identification of variants in cyclin D1 (CCND1) and B-Cell CLL/lymphoma 2 (BCL2). J Hum Genet. 2004;49(8):449–54.PubMedCrossRef Park BL, Kim LH, Cheong HS, Cho HY, Kim EM, Shin HD, Kim YS, Lee C. Identification of variants in cyclin D1 (CCND1) and B-Cell CLL/lymphoma 2 (BCL2). J Hum Genet. 2004;49(8):449–54.PubMedCrossRef
28.
Zurück zum Zitat Bachmann HS, Otterbach F, Callies R, Nuckel H, Bau M, Schmid KW, Siffert W, Kimmig R. The AA genotype of the regulatory BCL2 promoter polymorphism (938C>A) is associated with a favorable outcome in lymph node negative invasive breast cancer patients. Clin Cancer Res. 2007;13(19):5790–7.PubMedCrossRef Bachmann HS, Otterbach F, Callies R, Nuckel H, Bau M, Schmid KW, Siffert W, Kimmig R. The AA genotype of the regulatory BCL2 promoter polymorphism (938C>A) is associated with a favorable outcome in lymph node negative invasive breast cancer patients. Clin Cancer Res. 2007;13(19):5790–7.PubMedCrossRef
29.
Zurück zum Zitat Heubner M, Wimberger P, Otterbach F, Kasimir-Bauer S, Siffert W, Kimmig R, Nuckel H. Association of the AA genotype of the BCL2 (-938C > A) promoter polymorphism with better survival in ovarian cancer. Int J Biol Markers. 2009;24(4):223–9.PubMed Heubner M, Wimberger P, Otterbach F, Kasimir-Bauer S, Siffert W, Kimmig R, Nuckel H. Association of the AA genotype of the BCL2 (-938C > A) promoter polymorphism with better survival in ovarian cancer. Int J Biol Markers. 2009;24(4):223–9.PubMed
30.
Zurück zum Zitat Hirata H, Hinoda Y, Kikuno N, Suehiro Y, Shahryari V, Ahmad AE, Tabatabai ZL, Igawa M, Dahiya R. Bcl2–938C/A polymorphism carries increased risk of biochemical recurrence after radical prostatectomy. J Urol. 2009;181(4):1907–12.PubMedCrossRef Hirata H, Hinoda Y, Kikuno N, Suehiro Y, Shahryari V, Ahmad AE, Tabatabai ZL, Igawa M, Dahiya R. Bcl2–938C/A polymorphism carries increased risk of biochemical recurrence after radical prostatectomy. J Urol. 2009;181(4):1907–12.PubMedCrossRef
31.
Zurück zum Zitat Young RL, Korsmeyer SJ. A negative regulatory element in the bcl-2 5′-untranslated region inhibits expression from an upstream promoter. Mol Cell Biol. 1993;13(6):3686–97.PubMed Young RL, Korsmeyer SJ. A negative regulatory element in the bcl-2 5′-untranslated region inhibits expression from an upstream promoter. Mol Cell Biol. 1993;13(6):3686–97.PubMed
32.
Zurück zum Zitat Nuckel H, Frey UH, Bau M, Sellmann L, Stanelle J, Durig J, Jockel KH, Duhrsen U, Siffert W. Association of a novel regulatory polymorphism (-938C>A) in the BCL2 gene promoter with disease progression and survival in chronic lymphocytic leukemia. Blood. 2007;109(1):290–7.PubMedCrossRef Nuckel H, Frey UH, Bau M, Sellmann L, Stanelle J, Durig J, Jockel KH, Duhrsen U, Siffert W. Association of a novel regulatory polymorphism (-938C>A) in the BCL2 gene promoter with disease progression and survival in chronic lymphocytic leukemia. Blood. 2007;109(1):290–7.PubMedCrossRef
33.
Zurück zum Zitat Bachmann HS, Heukamp LC, Schmitz KJ, Hilburn CF, Kahl P, Buettner R, Nuckel H, Eisenhardt A, Rubben H, Schmid KW, et al. Regulatory BCL2 promoter polymorphism (-938C>A) is associated with adverse outcome in patients with prostate carcinoma. Int J Cancer. 2011;129(10):2390–9.PubMedCrossRef Bachmann HS, Heukamp LC, Schmitz KJ, Hilburn CF, Kahl P, Buettner R, Nuckel H, Eisenhardt A, Rubben H, Schmid KW, et al. Regulatory BCL2 promoter polymorphism (-938C>A) is associated with adverse outcome in patients with prostate carcinoma. Int J Cancer. 2011;129(10):2390–9.PubMedCrossRef
34.
Zurück zum Zitat Stewart WB, Kleihues P. World cancer report. Lyon: IARC Press; 2003, ISBN 92-832-0411-5. Stewart WB, Kleihues P. World cancer report. Lyon: IARC Press; 2003, ISBN 92-832-0411-5.
Metadaten
Titel
The -938A/A genotype of BCL2 gene is associated with esophageal cancer
verfasst von
Zhigang Liu
Ruifang Sun
Weidong Lü
Chengxue Dang
Yangrong Song
Cheng Wang
Xi Zhang
Le Han
Hao Cheng
Wei Gao
Jia Liu
Guangyan Lei
Publikationsdatum
01.12.2012
Verlag
Springer US
Erschienen in
Medical Oncology / Ausgabe 4/2012
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-011-0135-2

Weitere Artikel der Ausgabe 4/2012

Medical Oncology 4/2012 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.